NAD+: an essential coenzyme, but infusion benefits remain unproven

## What is it? Nicotinamide adenine dinucleotide (NAD+) is a coenzyme involved in energy metabolism and cellular reactions. It is not a peptide. NAD+ infusions are marketed for energy and healthy aging, but the claim that adding it improves those outcomes requires direct clinical testing. [1]

## What do studies show? A small pilot study compared eight people receiving a six-hour intravenous NAD+ infusion with three controls. It measured plasma and urinary NAD+ metabolites. Some plasma metabolites did not change until after two hours, while certain urinary excretion products rose later. The study was about handling of infused NAD+, not fatigue, exercise performance, cognitive function, biological age, or lifespan. It cannot establish those claimed benefits. [1]

## Safety The pilot was too small and brief to establish adverse-event rates or long-term infusion safety. Infusion services also depend on clinical monitoring and product quality. Results for oral NAD+ precursors should not be treated as evidence for an intravenous NAD+ vial. [1]

## How much? The pilot used 3 micromoles per minute by intravenous infusion for six hours as a metabolism experiment. That research rate is not an effective dose for energy or aging and cannot be translated into a self-use protocol. No established benefit-based or independently verifiable exact-product anecdotal dose was identified. [1]